Redcare Pharmacy NV (RDC) Fair Value & Analysis
Healthcare · DE · Market cap €1.4B
Fair value as of: Aug 13, 2026
From 2 valuation models · updated today
Share price −7.7% over the past month.
Below-average quality, and screening another 78% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (€20.77). The favourable scenario is already priced in.
- Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The model range is unusually wide (€6.04 to €20.77). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range €30.86 – €175.50 · fair‑value band €6.04 – €20.77 · the €61.15 price screens above the €13.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Redcare Pharmacy NV (RDC) currently trades at €61.15, while our model-based Fair Value estimate is €13.41, implying the stock looks roughly 78.1% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Redcare Pharmacy NV generated revenue of €3.1B at a net margin of -1.2%. Revenue grew 18.4% year over year. It earns a return on equity of -8.1%. Net debt stands at €323M. Fundamentals as of Aug 13, 2026
Our scenario range runs from €6.04 (bear case) to €20.77 (bull case); at €61.15, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 48% below its 52-week high and 102% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -78%, RDC screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 2 models by family
Widest divergence: Multiples (€21.05) versus Asset-Based (€15.30). Highest evidence: EV/EBITDA (54).
Notify me when RDC reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 26
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Redcare Pharmacy NV operates the online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. It offers prescription and non-prescription over-the-counter pharmaceuticals, beauty and personal care products, and food supplements. The company was formerly known as Shop Apotheke Europe N.V.
Full company description
Redcare Pharmacy NV operates the online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. It offers prescription and non-prescription over-the-counter pharmaceuticals, beauty and personal care products, and food supplements. The company was formerly known as Shop Apotheke Europe N.V. and changed its name to Redcare Pharmacy NV in June 2023. Redcare Pharmacy NV was founded in 2001 and is based in Sevenum, the Netherlands.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Redcare Pharmacy NV reported revenue of €2.9B in FY2025 versus €1.1B in FY2021, a compound +29.1%/yr. Reported net income was −€37.7M in FY2025.
RDC screens 78% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 63 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | -14% |
| Raia Drogasil S.A RADL3 | R$18.00 | R$15.58 | -13% |
| Alibaba Health Information Technology Limited 0241 | HK$3.33 | HK$2.04 | -39% |
| Yifeng Pharmacy Chain Co 603939 | ¥24.03 | ¥29.07 | +21% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.14 | ¥23.86 | +32% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 726.02 MXN | +57% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥13.44 | ¥10.57 | -21% |
| MedPlus Health Services Limited MEDPLUS | ₹675.05 | ₹379.25 | -44% |
| Yixintang Pharmaceutical Group 002727 | ¥12.29 | ¥9.45 | -23% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.51 | ¥10.05 | -39% |
Compare Redcare Pharmacy NV with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Redcare Pharmacy NV (RDC) overvalued or undervalued?
What is the fair value of RDC?
What is the quality score of RDC?
What is the revenue of Redcare Pharmacy NV (RDC)?
What is the net profit margin of RDC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Redcare Pharmacy NV and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.